Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer Journal Article


Authors: Francis, P.; Schneider, J.; Hann, L.; Balmaceda, C.; Barakat, R.; Phillips, M.; Hakes, T.
Article Title: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
Abstract: Purpose: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with platinum-refractory ovarian cancer. Patients and Methods: Twenty-five patients with platinum-refractory advanced ovarian cancer were treated. Twenty of the patients had failed to respond to platinum-based front-line chemotherapy and five had failed to respond to platinum-based therapy repeated at relapse. One patient had received prior pelvic radiation therapy. Patients were required to have bidimensionally measurable disease. Docetaxel was administered at ct dose of 100 mg/m(2) intravenously (IV) over 1 hour every 21 days. Twenty patients received no corticosteroid premedication and five received premedication with corticosteroids and antihistamines. Results: Eight of 23 assessable patients (35%) had a partial response (PR; 95% confidence interval, 16% to 57%). The median response duration was 5 months. Hospitalization for toxicity, predominantly neutropenic fever, occurred in 12 patients (48%) and 16% of courses. Anemia was common in the study population. Nonhematologic toxicities included alopecia, rash, fluid retention, diarrhea, peripheral neuropathy, and hypersensitivity reactions. Conclusion: Docetaxel demonstrates significant activity in patients with platinum-refractory advanced ovarian cancer. Routine premedication is recommended. Further investigations of this agent in ovarian cancer, including combinations with other active agents, appear indicated. (C) 1994 by American Society of Clinical Oncology.
Keywords: analogs; colony-stimulating factor; taxol; invitro; intravenous-infusion; taxotere rp-56976; nsc-628503
Journal Title: Journal of Clinical Oncology
Volume: 12
Issue: 11
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 1994-11-01
Start Page: 2301
End Page: 2308
Language: English
ACCESSION: WOS:A1994PP88000012
DOI: 10.1200/jco.1994.12.11.2301
PROVIDER: wos
PUBMED: 7964944
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard R Barakat
    629 Barakat
  2. Lucy E Hann
    69 Hann
  3. Prudence A. Francis
    16 Francis